Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHX9 | Q08211 | 1/20 | 0.53 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25429881 | 1.00 | DHX9 (0.53) | DHX9ALKBH1NAMPTMEN1PKM | |
| SCHEMBL25431256 | 0.88 | DHX9 (0.52) | DHX9ALKBH1NAMPTMEN1PKM | |
| SCHEMBL30535132 | 0.88 | DHX9 (0.52) | DHX9ALKBH1NAMPTMEN1PKM | |
| SCHEMBL31560926 | 0.87 | ALKBH1 (0.45) | DHX9ALKBH1MEN1PKMKMT2A | |
| SCHEMBL30543989 | 0.87 | DHX9 (0.70) | DHX9ALKBH1NAMPTHPGDMALT1 | |
| SCHEMBL25433507 | 0.87 | DHX9 (0.70) | DHX9ALKBH1NAMPTHPGDMALT1 | |
| SCHEMBL25999038 | 0.86 | DHX9 (0.50) | DHX9ALKBH1NAMPTMEN1PKM | |
| SCHEMBL26004607 | 0.85 | DHX9 (0.49) | DHX9ALKBH1NAMPTMEN1PKM | |
| SCHEMBL25430405 | 0.85 | DHX9 (0.47) | DHX9ALKBH1NAMPTMEN1PKM | |
| SCHEMBL30535407 | 0.85 | DHX9 (0.47) | DHX9ALKBH1NAMPTMEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145597-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-119923385-A | Inhibitors of RNA helicase DHX9 and uses thereof | 埃克森特治疗公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025080900-A1 | INHIBITORS OF THE RNA HELICASE DHX9 FOR USE IN THE TREATMENT OF DNA DAMAGE REPAIR DEFICIENT, HOMOLOGOUS RECOMBINATION DEFICIENT, AND CANCERS HAVING A BRCA LOSS OF FUNCTION MUTATION | ACCENT THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-12233065-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4479138-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | Accent Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12162867-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240316047-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20240279210-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316047-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX29, DHX9, DDX39B | DHX9 2/4885ALKBH1 884/4885NAMPT 2027/4885 |
| US-20240279210-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX29, DHX9, DDX39B | DHX9 2/4885ALKBH1 1233/4885NAMPT 1750/4885 |
| US-12233065-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | DHX29, DHX9, DDX39B | DHX9 2/4885ALKBH1 884/4885NAMPT 2027/4885 |
| US-12162867-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | DHX29, DHX9, DDX39B | DHX9 2/4885ALKBH1 1233/4885NAMPT 1750/4885 |
| US-20250145597-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | DHX9 1/4885ALKBH1 845/4885NAMPT 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.